Research progress in the mechanism of BRAF inhibitor resistance in melanoma
10.12092/j.issn.1009-2501.2020.05.015
- VernacularTitle: 黑色素瘤BRAF抑制剂耐药机制的研究进展
- Author:
Cheng WANG
1
Author Information
1. Dermatology Hospital, Chinese Academy of Medical Sciences
- Publication Type:Journal Article
- Keywords:
BRAF inhibitors;
Melanoma;
Resistance mechanism;
Treatment strategies
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2020;25(5):576-583
- CountryChina
- Language:Chinese
-
Abstract:
Melanoma is a malignant tumor of melanocyte origin, and BRAF mutations occur in about 50% of melanoma patients clinically. BRAF inhibitors can target mutated BRAF sites, thus rapidly inhibiting the proliferation and promoting apoptosis of tumor cells. However, the subsequent rapid occurrence of drug resistance events seriously restricted the continuous use of such drugs, so it is of great importance to explore the mechanism of BRAF inhibitors resistance. This paper introduces the research progress of BRAF inhibitor resistance in melanoma in recent years, in order to provide some references for the follow-up research and clinical application.
